Meredith Goldwasser
About Meredith Goldwasser
Meredith Goldwasser, Sc.D., is Senior Vice President, Strategy and Corporate Operations at Prime Medicine, serving in this role since September 2020. She holds a Sc.D. in Biostatistics from Harvard and a B.A. in Psychology from the University of Pennsylvania, and was age 54 as of April 22, 2025 . Prior to Prime Medicine, she led clinical development and biometrics functions at Agios and Novartis, with a focus on oncology and hematology programs, bringing deep biostatistics and operational leadership to PRME’s portfolio . Company-level TSR or EBITDA performance metrics tied to her tenure are not disclosed in proxy or filings; skip.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Agios Pharmaceuticals | Vice President & Development Lead, IDH Hematology | Nov 2017 – Sep 2020 | Led development for IDH hematology program, aligning clinical strategy with portfolio objectives |
| Agios Pharmaceuticals | Oncology Business Development Lead | Jul 2019 – Sep 2020 | Drove oncology BD leadership; asset evaluation and strategic partnering (scope per title) |
| Agios Pharmaceuticals | Vice President & Head of Biometrics and Data Management | Aug 2014 – Jul 2019 | Built and led biometrics and data management capabilities for clinical programs |
| Novartis International AG | U.S. Group Head of Biostatistics & Oncology Translational Medicine | Feb 2011 – Jul 2014 | Directed biostatistics and translational oncology across U.S. programs |
External Roles
- No external public-company directorships or outside board roles disclosed for Goldwasser in PRME proxy statements reviewed .
Fixed Compensation
- Goldwasser is not listed as a Named Executive Officer (NEO) in PRME’s 2023–2025 proxy compensation tables; therefore, base salary, target bonus %, and actual bonus paid are not disclosed in SEC compensation tables for her .
- Perquisites such as commuting reimbursements are discussed for certain NEOs but not attributed to Goldwasser; skip for lack of disclosure .
Performance Compensation
- Stock awards (RSUs/PSUs), options, performance metrics, and payout details are disclosed for NEOs only; no grant-date values, targets, or vesting schedules for Goldwasser are provided in proxy tables .
- Company policy emphasizes time-based and performance-based equity for NEOs; no Goldwasser-specific performance weighting or payout disclosure is available; skip .
Equity Ownership & Alignment
- Beneficial ownership tables list directors and NEOs; Goldwasser is not included, so total shares, % ownership, and vested vs unvested breakdowns are not disclosed in these tables .
- Hedging and pledging: PRME’s insider trading policy prohibits short sales, derivative transactions, and hedging; pledging is prohibited to mitigate forced sales risk, applicable to officers including Goldwasser .
- Rule 10b5-1 plans: PRME permits adoption of compliant trading plans; sales under such plans may occur at any time consistent with Rule 10b5-1, reducing discretionary timing risk signals .
- Compensation recovery (clawback): Board adopted a policy effective Oct 2, 2023 to recoup incentive comp tied to financial reporting measures upon a restatement, applicable to current and former executive officers .
- Stock ownership guidelines for executives are not disclosed in the proxies reviewed; skip.
Employment Terms
- No Goldwasser-specific employment agreement, severance multiple, non-compete/non-solicit, garden leave, consulting arrangements, or change-of-control terms are disclosed in proxy narrative (CEO terms are detailed separately and do not apply to Goldwasser) .
- Title and role continuity are disclosed: Senior Vice President, Strategy and Corporate Operations since September 2020 .
Performance & Track Record
- Strategic achievements: Leadership of IDH hematology development at Agios and oversight of biometrics/data management; prior U.S. biostatistics and translational oncology leadership at Novartis .
- Company-level stock or TSR performance tied specifically to Goldwasser’s tenure is not disclosed; skip.
Board Governance
- Goldwasser is not a director; committee memberships, attendance, independence status, or director compensation do not apply .
Compensation Peer Group and Say-on-Pay
- Peer group composition and say-on-pay outcomes are discussed at company level in proxies but not tied to Goldwasser-specific compensation; skip for her individual analysis.
Risk Indicators & Red Flags
- Hedging/pledging prohibited (reduces misalignment/forced sale risk) .
- Clawback policy exists (recoupment on restatements for incentive comp tied to financial reporting measures) .
- Section 16 compliance noted for 2022 generally; no Goldwasser-specific delinquency mentioned .
Investment Implications
- Alignment visibility: Absence of Goldwasser in NEO disclosures limits visibility into her cash/equity mix, performance metrics, and vesting schedules; investors lack data to assess pay-for-performance alignment or near-term insider selling pressure from vesting events .
- Policy mitigants: Company-wide prohibitions on hedging/pledging and adoption of 10b5-1 plans reduce trading-related risk signals; clawback policy strengthens governance around incentive comp tied to financials .
- Monitoring: Track future DEF 14A filings and Form 4 insider reports to quantify ownership, grants, and any sales by Goldwasser; without these, retention risk and incentive alignment remain undisclosed.